Inovio Pharmaceuticals, Inc. (INO)
After hours:
| Previous close | 7.29 |
| Open | 6.93 |
| Bid | 0.00 x 3100 |
| Ask | 0.00 x 1800 |
| Day's range | 6.91 - 7.32 |
| 52-week range | 5.81 - 19.00 |
| Volume | |
| Avg. volume | 3,666,578 |
| Market cap | 1.523B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.11 |
| Earnings date | 28 Feb 2022 - 04 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
- Motley Fool
Battle of the COVID Vaccine Contenders: Inovio vs. Ocugen
Inovio Pharmaceuticals (NASDAQ: INO) and Ocugen (NASDAQ: OCGN) are two small biotechs that hope to win regulatory authorizations for COVID-19 vaccines in the not-too-distant future. In this Motley Fool Live video recorded on Nov. 10, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss how these two COVID-19 contenders stack up against each other. Keith Speights: There are two companies that hope to market COVID-19 vaccines: Inovio and Ocugen.
- Motley Fool
3 Vaccine Latecomers That Could Double Your Money
Experts predict the coronavirus will stick around -- so a potential end to the pandemic wouldn't necessarily equal an end to the need for vaccination. In fact, you may see bigger returns from an investment in a smaller biotech company that hasn't yet reached the vaccine finish line. Positive clinical trial reports or regulatory submissions could be major catalysts.
- Motley Fool
Does This News Make Inovio Pharmaceuticals Stock a Buy?
The company is closer than ever to launching its coronavirus vaccine -- but will it be good enough to make the stock worth purchasing?
